New Diabetes Treatment Guidelines to Save Lives and Cut NHS Costs
Millions of people with type 2 diabetes in the UK are set to benefit from updated treatment guidelines issued by the National Institute for Health and Care Excellence (NICE) on February 18, 2026. The new recommendations prioritize earlier access to SGLT-2 inhibitors, a class of drugs proven to protect the heart and kidneys, and are projected to prevent around 17,000 deaths over three years across the UK.1
Shifting the First-Line Treatment Approach
Historically, metformin has been the standard first-line treatment for newly diagnosed type 2 diabetes. The updated NICE guidance now recommends offering metformin in combination with an SGLT-2 inhibitor as the initial treatment for most patients.1 SGLT-2 inhibitors work by helping the kidneys remove excess sugar from the body.
Significant Cost Savings for the NHS
The implementation of these new guidelines is also expected to generate substantial savings for the National Health Service (NHS). The availability of generic dapagliflozin, a commonly prescribed SGLT-2 inhibitor, is projected to result in cumulative savings of £560 million for 2025/26 and 2026/27.1 These funds can be reinvested into other areas of diabetes care, such as education programs and community support services, or allocated to other NHS priorities.
Evidence Supporting the New Guidelines
Research supporting the updated guidelines includes a trial emulation in UK primary care data analyzing data from 60,000 people with type 2 diabetes. The study found that individuals prescribed SGLT-2 inhibitors were 24% less likely to experience premature death over an average of three years compared to those receiving alternative blood sugar-lowering medications.2
Addressing Health Disparities in Treatment Access
NICE analysis has revealed that SGLT-2 inhibitors have historically been underprescribed to certain demographic groups, including women, older individuals, and Black people.2 The new guidance emphasizes the importance of a patient-centered approach, urging healthcare professionals to assess each patient’s heart and kidney health before initiating treatment and to introduce new medications one at a time to ensure tolerance.
Expanded Access to GLP-1 Receptor Agonists and Tirzepatide
In addition to SGLT-2 inhibitors, access to GLP-1 receptor agonists (such as semaglutide, dulaglutide, and liraglutide) and tirzepatide has been significantly expanded.3 These medications are now recommended for individuals with type 2 diabetes who have cardiovascular disease caused by blocked arteries, those diagnosed before the age of 40, or those living with obesity.3 Approximately 810,000 more people are expected to become eligible for these treatments as a result of the updated guidance.3
Slow-Release Metformin Recommended
To improve patient adherence, the guidance also recommends the use of slow-release metformin formulations, as stomach side effects are a common reason for patients discontinuing the standard-release version.
Key Takeaways
- New NICE guidelines recommend metformin plus an SGLT-2 inhibitor as first-line treatment for most type 2 diabetes patients.
- The changes are projected to prevent 17,000 deaths over three years in the UK.1
- Generic dapagliflozin will save the NHS an estimated £560 million.1
- Access to GLP-1 receptor agonists and tirzepatide has been expanded for specific patient groups.3
- Efforts are being made to address disparities in treatment access for women, older people, and Black people.2
These updated guidelines represent a significant step forward in the management of type 2 diabetes, offering the potential for improved patient outcomes, reduced healthcare costs, and a more equitable approach to treatment.
References:
- National Institute for Health and Care Excellence (NICE). Major changes to type 2 diabetes treatment could save thousands of lives. February 18, 2026. https://www.nice.org.uk/news/articles/major-changes-to-type-2-diabetes-treatment-could-save-thousands-of-lives
- https://www.bmj.com/content/392/bmj.s333
- Pharmaceutical Journal. NICE widens access to SGLT-2 inhibitors and GLP-1s in updated type 2 diabetes guidance. https://pharmaceutical-journal.com/article/news/nice-widens-access-to-sglt-2-inhibitors-and-glp-1s-in-updated-type-2-diabetes-guidance